KEGG   PATHWAY: opi05224
Entry
opi05224                    Pathway                                
Name
Breast cancer - Ochotona princeps (American pika)
Description
Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.
Class
Human Diseases; Cancer: specific types
Pathway map
opi05224  Breast cancer
opi05224

Organism
Ochotona princeps (American pika) [GN:opi]
Gene
101521523  ESR1; estrogen receptor isoform X2 [KO:K08550]
101527550  ESR2; LOW QUALITY PROTEIN: estrogen receptor beta [KO:K08551]
101521463  NCOA1; nuclear receptor coactivator 1 [KO:K09101] [EC:2.3.1.48]
101524171  NCOA3; nuclear receptor coactivator 3 [KO:K11256] [EC:2.3.1.48]
101526067  FOS; proto-oncogene c-Fos isoform X1 [KO:K04379]
101521685  JUN; transcription factor AP-1 [KO:K04448]
101533630  SP1; transcription factor Sp1 isoform X1 [KO:K04684]
101531631  CCND1; G1/S-specific cyclin-D1 isoform X2 [KO:K04503]
101522285  MYC; myc proto-oncogene protein [KO:K04377]
101524403  PGR; progesterone receptor isoform X1 [KO:K08556]
101526533  WNT1; proto-oncogene Wnt-1 [KO:K03209]
101532229  WNT4; protein Wnt-4 [KO:K00408]
101532341  TNFSF11; tumor necrosis factor ligand superfamily member 11 isoform X1 [KO:K05473]
101526376  tumor necrosis factor ligand superfamily member 11-like [KO:K05473]
101527578  ERBB2; receptor tyrosine-protein kinase erbB-2 isoform X4 [KO:K05083] [EC:2.7.10.1]
101529368  FGF1; fibroblast growth factor 1 [KO:K18496]
101520285  FGF2; LOW QUALITY PROTEIN: fibroblast growth factor 2 [KO:K18497]
101535653  FGF20; fibroblast growth factor 20 [KO:K04358]
101519475  FGF4; fibroblast growth factor 4 [KO:K04358]
101519725  FGF3; fibroblast growth factor 3 [KO:K04358]
101535784  FGF5; fibroblast growth factor 5 [KO:K04358]
101519353  FGF10; fibroblast growth factor 10 [KO:K04358]
101532472  FGF16; fibroblast growth factor 16 [KO:K04358]
101518744  FGF9; fibroblast growth factor 9 [KO:K04358]
101520631  FGF7; fibroblast growth factor 7 [KO:K04358]
101522068  FGF17; fibroblast growth factor 17 [KO:K04358]
101533103  FGF18; fibroblast growth factor 18 [KO:K04358]
101521180  FGF22; fibroblast growth factor 22 [KO:K04358]
101524610  FGF8; fibroblast growth factor 8 isoform X3 [KO:K04358]
101528594  FGF6; fibroblast growth factor 6 [KO:K04358]
101519227  FGF19; fibroblast growth factor 19 [KO:K22603]
101533375  FGF21; fibroblast growth factor 21 [KO:K22429]
101528351  FGF23; fibroblast growth factor 23 [KO:K22428]
101534918  FGFR1; fibroblast growth factor receptor 1 isoform X1 [KO:K04362] [EC:2.7.10.1]
101526004  IGF1; insulin-like growth factor I isoform X2 [KO:K05459]
101535483  IGF1R; insulin-like growth factor 1 receptor isoform X1 [KO:K05087] [EC:2.7.10.1]
101536206  EGF; pro-epidermal growth factor [KO:K04357]
101536689  KIT; mast/stem cell growth factor receptor Kit [KO:K05091] [EC:2.7.10.1]
101529134  SHC1; SHC-transforming protein 1 isoform X1 [KO:K06279]
101522080  SHC2; SHC-transforming protein 2 [KO:K17447]
101522287  SHC3; SHC-transforming protein 3 [KO:K17448]
101535980  SHC4; SHC-transforming protein 4 [KO:K17449]
101531037  GRB2; growth factor receptor-bound protein 2 isoform X1 [KO:K04364]
101534610  SOS1; son of sevenless homolog 1 isoform X1 [KO:K03099]
101525349  SOS2; son of sevenless homolog 2 isoform X1 [KO:K03099]
101531636  HRAS; GTPase HRas [KO:K02833]
101534080  KRAS; GTPase KRas isoform X1 [KO:K07827]
101524465  NRAS; GTPase NRas [KO:K07828]
101529871  ARAF; serine/threonine-protein kinase A-Raf [KO:K08845] [EC:2.7.11.1]
101526188  BRAF; serine/threonine-protein kinase B-raf isoform X2 [KO:K04365] [EC:2.7.11.1]
101534290  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X2 [KO:K04366] [EC:2.7.11.1]
101533612  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
105942099  LOW QUALITY PROTEIN: dual specificity mitogen-activated protein kinase kinase 2-like [KO:K04369] [EC:2.7.12.2]
101529486  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
101530701  MAPK3; mitogen-activated protein kinase 3 isoform X1 [KO:K04371] [EC:2.7.11.24]
101525427  mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
101519449  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
101533851  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X3 [KO:K00922] [EC:2.7.1.153]
101533024  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
101532354  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
101517982  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
101528030  phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
101529935  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
101533296  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
101519021  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
101525801  AKT3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
101525384  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
101526118  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
101528246  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
101526503  JAG1; protein jagged-1 [KO:K06052]
101534466  JAG2; protein jagged-2 [KO:K21635]
101517037  DLL4; delta-like protein 4 [KO:K06051]
101525221  DLL3; delta-like protein 3 [KO:K06051]
101530411  DLL1; delta-like protein 1 [KO:K06051]
101529560  NOTCH1; neurogenic locus notch homolog protein 1 [KO:K02599]
101520325  NOTCH2; neurogenic locus notch homolog protein 2 [KO:K20994]
101533047  NOTCH3; neurogenic locus notch homolog protein 3 [KO:K20995]
101535420  NOTCH4; LOW QUALITY PROTEIN: neurogenic locus notch homolog protein 4 [KO:K20996]
101517364  HES1; transcription factor HES-1 [KO:K06054]
101534326  HEYL; hairy/enhancer-of-split related with YRPW motif-like protein [KO:K09091]
101518794  HEY2; hairy/enhancer-of-split related with YRPW motif protein 2 [KO:K09091]
101521630  HEY1; hairy/enhancer-of-split related with YRPW motif protein 1 isoform X2 [KO:K09091]
101532426  FLT4; vascular endothelial growth factor receptor 3 [KO:K05097] [EC:2.7.10.1]
101522490  CDKN1A; cyclin-dependent kinase inhibitor 1 [KO:K06625]
101533623  NFKB2; nuclear factor NF-kappa-B p100 subunit [KO:K04469]
101519545  WNT2; protein Wnt-2 [KO:K00182]
101535993  WNT2B; protein Wnt-2b [KO:K00182]
101531097  WNT3A; protein Wnt-3a [KO:K00312]
101519718  WNT3; proto-oncogene Wnt-3 [KO:K00312]
101533147  WNT5B; protein Wnt-5b [KO:K00444]
101526139  WNT5A; protein Wnt-5a [KO:K00444]
101518428  WNT6; protein Wnt-6 [KO:K00445]
101525411  WNT7A; protein Wnt-7a isoform X1 [KO:K00572]
101527317  WNT7B; protein Wnt-7b isoform X1 [KO:K00572]
101535038  WNT8A; protein Wnt-8a [KO:K00714]
101530831  WNT8B; protein Wnt-8b [KO:K00714]
101535462  WNT9A; protein Wnt-9a [KO:K01064]
101519468  WNT9B; protein Wnt-9b [KO:K01064]
101526780  WNT10B; protein Wnt-10b [KO:K01357]
101518185  WNT10A; protein Wnt-10a [KO:K01357]
101530628  WNT11; protein Wnt-11 isoform X1 [KO:K01384]
101521646  WNT16; protein Wnt-16 [KO:K01558]
101528861  FZD1; frizzled-1 [KO:K02432]
101519819  FZD7; frizzled-7 [KO:K02432]
101520542  FZD2; frizzled-2 [KO:K02235]
101528374  FZD3; frizzled-3 [KO:K02329]
101518239  FZD4; frizzled-4 [KO:K02354]
101532093  FZD5; frizzled-5 [KO:K02375]
101517741  FZD8; frizzled-8 [KO:K02375]
101524151  FZD6; frizzled-6 [KO:K02376]
101519524  FZD9; frizzled-9 [KO:K02842]
101520287  FZD10; frizzled-10 [KO:K02842]
101517031  LRP5; low-density lipoprotein receptor-related protein 5 [KO:K03068]
101517587  LRP6; low-density lipoprotein receptor-related protein 6 [KO:K03068]
101522688  DVL1; segment polarity protein dishevelled homolog DVL-1 [KO:K02353]
101528918  DVL3; segment polarity protein dishevelled homolog DVL-3 isoform X1 [KO:K02353]
101516456  DVL2; segment polarity protein dishevelled homolog DVL-2 isoform X1 [KO:K02353]
101520075  FRAT1; proto-oncogene FRAT1 [KO:K03069]
101533693  GSK3B; glycogen synthase kinase-3 beta isoform X1 [KO:K03083] [EC:2.7.11.26]
101533051  AXIN1; axin-1 isoform X1 [KO:K02157]
101522655  AXIN2; axin-2 isoform X1 [KO:K04385]
101516222  APC2; adenomatous polyposis coli protein 2 [KO:K02085]
101526321  APC; adenomatous polyposis coli protein [KO:K02085]
101528934  CTNNB1; catenin beta-1 isoform X1 [KO:K02105]
101535269  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101516751  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101520021  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101532141  LOW QUALITY PROTEIN: casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101519529  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101530782  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101530428  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101516511  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101519787  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101522229  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101518228  CSNK1A1; casein kinase I isoform X1 [KO:K08957] [EC:2.7.11.1]
101534687  casein kinase I-like [KO:K08957] [EC:2.7.11.1]
101526730  TCF7; transcription factor 7 isoform X2 [KO:K02620]
101522406  TCF7L1; transcription factor 7-like 1 [KO:K04490]
101521047  TCF7L2; transcription factor 7-like 2 isoform X4 [KO:K04491]
101525298  LEF1; lymphoid enhancer-binding factor 1 isoform X3 [KO:K04492]
101528346  TP53; cellular tumor antigen p53 [KO:K04451]
101516300  GADD45B; growth arrest and DNA damage-inducible protein GADD45 beta [KO:K04402]
101519285  GADD45A; growth arrest and DNA damage-inducible protein GADD45 alpha isoform X1 [KO:K04402]
101521693  GADD45G; growth arrest and DNA damage-inducible protein GADD45 gamma [KO:K04402]
101517703  BAX; apoptosis regulator BAX [KO:K02159]
101516199  BAK1; bcl-2 homologous antagonist/killer [KO:K14021]
101527969  DDB2; DNA damage-binding protein 2 [KO:K10140]
101528874  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
101530437  CDK4; cyclin-dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
101530682  CDK6; cyclin-dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
101517612  RB1; retinoblastoma-associated protein [KO:K06618]
101529862  E2F1; transcription factor E2F1 [KO:K17454]
101528728  E2F2; transcription factor E2F2 [KO:K09389]
101536117  E2F3; transcription factor E2F3 [KO:K06620]
101523476  BRCA1; breast cancer type 1 susceptibility protein [KO:K10605] [EC:2.3.2.27]
101531225  BRCA2; breast cancer type 2 susceptibility protein [KO:K08775]
Compound
C00410  Progesterone
C00951  Estradiol-17beta
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
PMID:24649067
  Authors
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  Title
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  Journal
Biomed Rep 2:41-52 (2014)
DOI:10.3892/br.2013.187
Reference
PMID:27390604
  Authors
Dai X, Xiang L, Li T, Bai Z
  Title
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
  Journal
J Cancer 7:1281-94 (2016)
DOI:10.7150/jca.13141
Reference
PMID:20436504
  Authors
Schnitt SJ
  Title
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
  Journal
Mod Pathol 23 Suppl 2:S60-4 (2010)
DOI:10.1038/modpathol.2010.33
Reference
PMID:23000897
  Authors
  Title
Comprehensive molecular portraits of human breast tumours.
  Journal
Nature 490:61-70 (2012)
DOI:10.1038/nature11412
Reference
PMID:22178455
  Authors
Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A
  Title
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
  Journal
Cancer Treat Rev 38:698-707 (2012)
DOI:10.1016/j.ctrv.2011.11.005
Reference
  Authors
Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.
  Title
Targeting androgen/estrogen receptors crosstalk in cancer
  Journal
Trends Cancer 2:35-48 (2016)
DOI:10.1016/j.trecan.2015.12.001
Reference
  Authors
Sharp A, Harper-Wynne C.
  Title
Treatment of advanced breast cancer (ABC): the expanding landscape of targeted therapies
  Journal
J Cancer Biol Res 2:1036 (2014)
Reference
PMID:24596345
  Authors
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S
  Title
Genetic and epigenetic aspects of breast cancer progression and therapy.
  Journal
Anticancer Res 34:1071-7 (2014)
Reference
PMID:23988612
  Authors
Mohamed A, Krajewski K, Cakar B, Ma CX
  Title
Targeted therapy for breast cancer.
  Journal
Am J Pathol 183:1096-112 (2013)
DOI:10.1016/j.ajpath.2013.07.005
Reference
PMID:22722193
  Authors
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
  Title
Whole-genome analysis informs breast cancer response to aromatase inhibition.
  Journal
Nature 486:353-60 (2012)
DOI:10.1038/nature11143
Reference
PMID:25907219
  Authors
Ma CX, Reinert T, Chmielewska I, Ellis MJ
  Title
Mechanisms of aromatase inhibitor resistance.
  Journal
Nat Rev Cancer 15:261-75 (2015)
DOI:10.1038/nrc3920
Reference
PMID:16113099
  Authors
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL
  Title
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
  Journal
Endocr Relat Cancer 12 Suppl 1:S47-59 (2005)
DOI:10.1677/erc.1.00993
Reference
PMID:24111892
  Authors
Dasgupta S, Lonard DM, O'Malley BW
  Title
Nuclear receptor coactivators: master regulators of human health and disease.
  Journal
Annu Rev Med 65:279-92 (2014)
DOI:10.1146/annurev-med-051812-145316
Reference
PMID:23702927
  Authors
Brisken C
  Title
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
  Journal
Nat Rev Cancer 13:385-96 (2013)
DOI:10.1038/nrc3518
Reference
PMID:20087430
  Authors
Scarpin KM, Graham JD, Mote PA, Clarke CL
  Title
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.
  Journal
Nucl Recept Signal 7:e009 (2009)
DOI:10.1621/nrs.07009
Reference
PMID:24291072
  Authors
Knutson TP, Lange CA
  Title
Tracking progesterone receptor-mediated actions in breast cancer.
  Journal
Pharmacol Ther 142:114-25 (2014)
DOI:10.1016/j.pharmthera.2013.11.010
Reference
PMID:25544707
  Authors
Dittrich A, Gautrey H, Browell D, Tyson-Capper A
  Title
The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
  Journal
J Mammary Gland Biol Neoplasia 19:253-70 (2014)
DOI:10.1007/s10911-014-9329-5
Reference
PMID:21965336
  Authors
Higgins MJ, Baselga J
  Title
Targeted therapies for breast cancer.
  Journal
J Clin Invest 121:3797-803 (2011)
DOI:10.1172/JCI57152
Reference
PMID:26028978
  Authors
Mukohara T
  Title
PI3K mutations in breast cancer: prognostic and therapeutic implications.
  Journal
Breast Cancer (Dove Med Press) 7:111-23 (2015)
DOI:10.2147/BCTT.S60696
Reference
PMID:19088017
  Authors
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA
  Title
Triple-negative breast cancer: risk factors to potential targets.
  Journal
Clin Cancer Res 14:8010-8 (2008)
DOI:10.1158/1078-0432.CCR-08-1208
Reference
PMID:21898546
  Authors
King TD, Suto MJ, Li Y
  Title
The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.
  Journal
J Cell Biochem 113:13-8 (2012)
DOI:10.1002/jcb.23350
Reference
PMID:11737884
  Authors
Brown AM
  Title
Wnt signaling in breast cancer: have we come full circle?
  Journal
Breast Cancer Res 3:351-5 (2001)
DOI:10.1186/bcr321
Reference
PMID:21076461
  Authors
Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS
  Title
beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
  Journal
Mod Pathol 24:209-31 (2011)
DOI:10.1038/modpathol.2010.205
Reference
PMID:20971825
  Authors
Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS
  Title
Notch signaling pathway as a therapeutic target in breast cancer.
  Journal
Mol Cancer Ther 10:9-15 (2011)
DOI:10.1158/1535-7163.MCT-10-0677
Reference
PMID:26968398
  Authors
Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS
  Title
Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
  Journal
Breast Cancer Res Treat 156:211-26 (2016)
DOI:10.1007/s10549-016-3746-7
Reference
PMID:26040571
  Authors
Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N
  Title
Therapeutic targets of triple-negative breast cancer: a review.
  Journal
Br J Pharmacol 172:4228-37 (2015)
DOI:10.1111/bph.13211
Reference
PMID:23196196
  Authors
Karamboulas C, Ailles L
  Title
Developmental signaling pathways in cancer stem cells of solid tumors.
  Journal
Biochim Biophys Acta 1830:2481-95 (2013)
DOI:10.1016/j.bbagen.2012.11.008
Reference
PMID:23881035
  Authors
Ignatiadis M, Sotiriou C
  Title
Luminal breast cancer: from biology to treatment.
  Journal
Nat Rev Clin Oncol 10:494-506 (2013)
DOI:10.1038/nrclinonc.2013.124
Reference
PMID:25013431
  Authors
Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH
  Title
Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.
  Journal
J Breast Cancer 17:113-20 (2014)
DOI:10.4048/jbc.2014.17.2.113
Reference
PMID:11879567
  Authors
Gasco M, Shami S, Crook T
  Title
The p53 pathway in breast cancer.
  Journal
Breast Cancer Res 4:70-6 (2002)
DOI:10.1186/bcr426
Reference
PMID:15343273
  Authors
Narod SA, Foulkes WD
  Title
BRCA1 and BRCA2: 1994 and beyond.
  Journal
Nat Rev Cancer 4:665-76 (2004)
DOI:10.1038/nrc1431
Related
pathway
opi03440  Homologous recombination
opi04010  MAPK signaling pathway
opi04110  Cell cycle
opi04115  p53 signaling pathway
opi04151  PI3K-Akt signaling pathway
opi04310  Wnt signaling pathway
opi04330  Notch signaling pathway
opi04915  Estrogen signaling pathway
KO pathway
ko05224   
LinkDB

DBGET integrated database retrieval system